Skip to content
RDL Network logo
PD-16 Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy — Claudia Angela Maria Fulgenzi (2023) | RDL Network